Alphatec (NASDAQ:ATEC) Share Price Crosses Above 200 Day Moving Average of $3.52

Alphatec Holdings Inc (NASDAQ:ATEC) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.52 and traded as high as $6.22. Alphatec shares last traded at $6.11, with a volume of 4,112 shares trading hands.

A number of research firms recently weighed in on ATEC. Zacks Investment Research upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Monday, May 13th. BidaskClub upgraded shares of Alphatec from a “hold” rating to a “buy” rating in a research note on Tuesday, August 13th. Piper Jaffray Companies began coverage on shares of Alphatec in a research note on Monday, August 5th. They set an “overweight” rating and a $7.00 target price on the stock. HC Wainwright lifted their target price on shares of Alphatec from $4.00 to $6.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. Finally, ValuEngine upgraded shares of Alphatec from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 8th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $6.50.

The company has a debt-to-equity ratio of 3.59, a quick ratio of 1.40 and a current ratio of 2.45. The company has a market capitalization of $360.18 million, a P/E ratio of -10.57 and a beta of 1.47. The business’s fifty day simple moving average is $5.00 and its 200-day simple moving average is $3.52.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Wednesday, July 24th. The medical technology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.05). The company had revenue of $27.32 million during the quarter, compared to the consensus estimate of $25.37 million. Alphatec had a negative net margin of 45.29% and a negative return on equity of 211.15%. As a group, analysts forecast that Alphatec Holdings Inc will post -0.91 EPS for the current year.

In other Alphatec news, EVP Craig E. Hunsaker sold 50,000 shares of Alphatec stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. Following the sale, the executive vice president now directly owns 811,112 shares in the company, valued at approximately $4,055,560. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Craig E. Hunsaker sold 100,000 shares of Alphatec stock in a transaction on Monday, August 12th. The shares were sold at an average price of $5.88, for a total transaction of $588,000.00. Following the completion of the sale, the executive vice president now owns 811,112 shares in the company, valued at $4,769,338.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 208,929 shares of company stock worth $1,167,913. 34.32% of the stock is currently owned by insiders.

Several institutional investors have recently bought and sold shares of the company. Royal Bank of Canada increased its holdings in shares of Alphatec by 143.2% in the 2nd quarter. Royal Bank of Canada now owns 6,686 shares of the medical technology company’s stock worth $30,000 after buying an additional 3,937 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Alphatec by 8.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 95,662 shares of the medical technology company’s stock worth $219,000 after buying an additional 7,705 shares during the last quarter. Advisor Group Inc. bought a new stake in shares of Alphatec in the 2nd quarter worth about $36,000. JPMorgan Chase & Co. bought a new stake in shares of Alphatec in the 2nd quarter worth about $36,000. Finally, Russell Investments Group Ltd. bought a new stake in shares of Alphatec in the 2nd quarter worth about $40,000. Hedge funds and other institutional investors own 14.79% of the company’s stock.

About Alphatec (NASDAQ:ATEC)

Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.

Featured Story: Convertible Shares

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.